ロード中...
Phase 0 Radiopharmaceutical–Agent Clinical Development
The evaluation of antibody-targeted or peptide-targeted radiopharmaceuticals as monotherapy or in oncological drug combinations requires programmatic collaboration within the National Cancer Institute (NCI) clinical trial enterprise. Phase 0 trials provide a flexible research platform for the study...
保存先:
| 出版年: | Front Oncol |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7461940/ https://ncbi.nlm.nih.gov/pubmed/33014772 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.01310 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|